AP5 could markedly inhibit AChE-induced Aβ aggregation in vitro and brain AChE catalytic activity in AD mice, which was consistent with the molecular docking result showing that AP5 could bind AChE through PAS and CAS. Here, ACHE is linked to Alzheimer disease.